Phase II
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
The company plans to move it into Phase III studies in APOL1-mediated kidney disease, including FSGS, in the first quarter of 2022.
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
Adagio claims that none of the mutations found in Omicron are linked with escape from ADG20 neutralization in vitro.
Two biopharma companies developing therapeutics in the oncology space begin the week with strong signals in Phase II.
As the late-stage trials continue to progress, Talaris is rapidly ramping up its resources and investments.
Treatment for non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, consists mainly of lifestyle modification – specifically dieting and weight loss.
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
Both Gilead Sciences and Merck announced they were pausing a Phase II trial of islatravir and lenacapavir in HIV.
PRESS RELEASES